Loading clinical trials...

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer | Clinical Trials | Clareo Health

UNKNOWNPHASE1/PHASE2

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer

Clinical Study Using Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer

NCT02873520•Ningbo Cancer Hospital

Summary

To evaluate the safety and effectiveness of cell therapy using Precision Cells to treat Advanced Gastric Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Gastric Cancer.

Detailed Description

A total of 40 patients may be enrolled over a period of 1-2 years.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18\~65 years old, male or female;
•2. Life expectancy≥6 months;
•3. ECOG score: 0-3;
•4. Advanced Malignancies (gastric cancer) were diagnosed by pathological or clinical physicians;
•5. Enough venous channel, no other contraindications to the separation and collection of white blood cells;
•6. Laboratory examination: white blood cell≥3 x 10\*9/L, blood platelet count≥60 x 10\*/L,hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level；
•7. Signed informed consent；8. Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion.

Exclusion Criteria

•1. Expected Overall survival \< 6 months;
•2. Patients with uncontrolled hypertension (\>160/95mmHg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (\> Class II, NYHA), or myocardial infarction within 6 months.
•3. Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc;
•4. Other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month.
•5. Unable or unwilling to provide informed consent, or fail to comply with the test requirements.

Locations (1)

Ningbo No.5 Hospital (Ningbo Cancer Hospital)

Ningbo, Zhejiang, China

Key Dates

Start Date

August 1, 2016

Primary Completion Date

March 1, 2018

Completion Date

August 1, 2018

Last Updated

October 7, 2016

Enrollment

ESTIMATED participants

Conditions

Precision Cell ImmunotherapyChemotherapyAdvanced Gastric Cancer

Interventions

Chemotherapy

DRUG

Precision Cell Immunotherapy

BIOLOGICAL

Contacts

Bi Wang

CONTACT

biwang0218@126.com

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

NCT07423390

Peripheral Neuropathy Due to ChemotherapyPeripheral Neuropathy, Chemotherapy-induced

View study

RECRUITINGNA

Comparing the Effects of Art Therapy and Mandala Application on State Anxiety Levels in Chemotherapy Patients

NCT07435597

Oncologic DiseaseChemotherapy

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 7, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer

Inclusion Criteria

Exclusion Criteria

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

Comparing the Effects of Art Therapy and Mandala Application on State Anxiety Levels in Chemotherapy Patients

Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)

Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy